Evaluated by: Aleodor Andea, MD ; Paul Wakely Jr., MD ; Raja Seethala, MD, March 16, 2016
Original release date: March 26, 2016
Access to this course expires on: March 15, 2019
There has been a remarkable increase in the knowledge about tumors, tumor development and tumor genetics in the past 15 years since the last long course devoted to head and neck pathology. Many new entities have been described, with their diagnostic criteria and ancillary supporting findings elucidated. The differential diagnostic considerations of the head and neck are broad, due in part to the wide diversity of organs, many tissue types, and the often very limited size of biopsy samples. The differences between benign, reactive lesions and lethal malignancies may be quite subtle. The primary goal of this course is to present practical, common, every-day cases across a broad spectrum of anatomic sites, discussing the development of differential diagnoses based on clinical and imaging findings, histologic features and additional techniques that allow for an appropriate diagnosis to be reached. These diagnoses are put in the context of management and outcome differences, highlighting entities that provoke a broad differential diagnosis. The major topics include sinonasal tract tumors, newly described and basaloid salivary gland tumors, oropharyngeal carcinomas, lichenoid lesions of the oral cavity, the viral-associated tumors of the nasopharynx, odontogenic cysts and tumors, squamous lesions of the larynx, with a focused discussion on how and when to use molecular and genetic techniques. Information to be included in the 2016-17 WHO classification are discussed. The lectures are intended for general surgical pathologists, oral pathologists and pathology residents and fellows.
Practicing academic and community pathologists, and pathologists-in-training
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 5.5 AMA PRA Category 1 CreditsTM
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABPath requirements for Continuing Certification (CC). Registrants must take and pass the post-test in order to claim SAMs credit.
Physicians can earn a maximum of 5.5 SAM credit hours.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships: Dr. Lester D. R. Thompson, Dr. Alena Skalova, Dr. James Lewis, Jr., Dr. Susan Muller, Dr. John K-C. Chan, Dr. Raja R. Seethala, Dr. Robert Robinson, Dr. Jennifer L. Hunt, Dr. Bruce M. Wenig
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.
To earn CME and SAM credit, all learners must take a content-based exam and achieve a minimum score of 80%. If learners do not achieve a passing score of 80%, they have the option to retake the exam. After you pass the test and complete the evaluation, your certificate of completion will be available to view and print by clicking here.
Handouts are located within the presentation, under the Resources
Purchasing as a bundle saves 10% over the individual purchase of each course.
Not A Member? Click Here